Back to results

Phase 1b Trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma

Objective

Estimate the RP2D of iberdomide in combination with teclistamab.

Protocol #

10620

Trial Phase:

Phase I

Principal Investigator:

Mann, Hashim

Cancer Type
  • Multiple Myeloma
Study Site
  • Virginia Commonwealth University

- Patients must have histologically or cytologically confirmed MM, as defined in the International Myeloma Working Group (IMWG) criteria
- If patients have undergone autologous SCT, Day 0 of SCT must be >100 days to be eligible for the study.
- Patients must have had disease progression after >/=4 prior lines of anti-myeloma treatments including one proteasome inhibitor

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Kristin Lantis, MSN, RN, CCRP
    Phone: +1 804-828-2177
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: